[HTML][HTML] Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

L Alder, D Trapani, C Bradbury… - NPJ Breast …, 2023 - nature.com
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic
breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily …

[HTML][HTML] Acute anemia

L Alder, A Tambe - 2019 - europepmc.org
Objectives: Describe the signs and symptoms of acute anemia that are likely to be present
when a patient has lost greater than twenty percent of their blood volume.

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical …

R Rahman, MYC Polley, L Alder, PK Brastianos… - The Lancet …, 2023 - thelancet.com
Successful drug development for people with cancers of the CNS has been challenging. There
are multiple barriers to successful drug development including biological factors, rarity of …

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor …

S Sammons, K Raskina, N Danziger, L Alder… - JCO Precision …, 2022 - ascopubs.org
PURPOSE APOBEC mutagenesis underlies somatic evolution and accounts for tumor
heterogeneity in several cancers, including breast cancer (BC). In this study, we evaluated the …

[PDF][PDF] Systemic Management of Brain Metastases in HER2+ Breast Cancer in 2022

L Alder, S Sammons… - … in Hematology & …, 2022 - hematologyandoncology.net
Up to half of all patients with metastatic human epidermal growth factor receptor 2–positive (HER2+)
breast cancer will eventually acquire brain metastases (BrMs), which are associated …

[HTML][HTML] Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma

HM Lee, L Alder, M Nguyen, SC Dougherty… - Journal of …, 2023 - ncbi.nlm.nih.gov
Background Yttrium-90 (Y90) radioembolization is a catheter-based therapy for hepatocellular
carcinoma (HCC). Multiple trials have evaluated the efficacy of Y90 in HCC; however, few …

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2+ breast cancer

L Noteware, G Broadwater, N Dalal, L Alder… - Breast Cancer Research …, 2023 - Springer
Purpose Current systemic therapy guidelines for patients with HER2 + breast cancer brain
metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth …

How to manage and monitor cardiac dysfunction in patients with metastatic her2-positive breast cancer

SF Dent, H Moore, P Raval, L Alder, A Guha - Cardio Oncology, 2022 - jacc.org
Highlights • Targeted therapies improve clinical outcomes in HER2+ metastatic breast
cancer. • There is thus far minimal signal of increased risk of cardiotoxicity from novel HER2 …

Durable clinical and radiographic responses in a series of patients with HER2+ Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab …

L Alder, D Trapani, A Van Swearingen, M Khasraw… - Cancer Research, 2022 - AACR
Background: LMD is a devastating clinical outcome of advanced BC with a median survival
of 4.4 months for the HER2+ subtype. There are few effective treatments for LMD. T-DXd has …

Initial match rates of an innovative international partnership: the Ochsner Clinical School experience

RE Deichmann, L Alder, L Seoane, WW Pinsky… - Ochsner …, 2016 - ochsnerjournal.org
… Dodd Denton is the Academic Head of General Medicine; and Laura Alder is a medical
student of The University of Queensland School of Medicine, Ochsner Clinical School. …